Only Select Incidental Thyroid Nodules Need Further Evaluation

Share this content:
Only Select Incidental Thyroid Nodules Need Further Evaluation
Only Select Incidental Thyroid Nodules Need Further Evaluation

MONDAY, April 24, 2017 (HealthDay News) -- Only a few select incidental thyroid nodules require further evaluation, according to a review published online April 20 in JAMA Otolaryngology-Head & Neck Surgery.

Jenny K. Hoang, M.B.B.S., from the Duke University Medical Center in Durham, N.C., and Xuan V. Nguyen, M.D., Ph.D., from The Ohio State University Wexner Medical Center in Columbus, discuss the risks and harms of management of incidental thyroid nodules.

The authors note that indiscriminate workup of incidental thyroid nodules with ultrasonography is not cost-effective and is potentially harmful. Evidence-based recommendations for incidental thyroid nodules include selection criteria for nodule workup based on suspicious imaging findings, patient age, and nodule size. In the absence of clinical risk factors or suspicious imaging findings, workup with dedicated thyroid ultrasonography is recommended only for nodules at least 1.5 or 1 cm in patients aged 35 years or older or younger than 35 years, respectively.

"The recommendations aim to promote identification of significant thyroid cancers, reduce unnecessary workup, and provide guidance for clinical practice," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths